StockData
SAB Biotherapeutics, Inc. logo

SAB Biotherapeutics, Inc. (SABS) stock

SABSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$2.95−0.05 (-1.67%)

Close on Nov 17, 2026Market cap $268.41MP/E –Yield –

SAB Biotherapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

SAB Biotherapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$53.94M. For fiscal 2025 it was -$44.78M. The highest annual figure on record is $10.00M in fiscal 2020.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$44.78M–
FY2024Dec 31, 2024-$34.29M–
FY2023Dec 31, 2023-$25.12M–
FY2022Dec 31, 2022-$23.46M-1280.7%
FY2021Dec 31, 2021$1.99M-80.1%
FY2020Dec 31, 2020$10.00M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.84M–
Q1 FY2026Mar 31, 2026-$14.27M–
Q4 FY2025Dec 31, 2025-$16.78M–
Q3 FY2025Sep 30, 2025-$13.05M–
Q2 FY2025Jun 30, 2025-$7.15M–
Q1 FY2025Mar 31, 2025-$7.80M–
Q4 FY2024Dec 31, 2024-$9.53M–
Q3 FY2024Sep 30, 2024-$6.29M–
Q2 FY2024Jun 30, 2024-$7.72M–
Q1 FY2024Mar 31, 2024-$10.75M–
Q4 FY2023Dec 31, 2023-$13.45M–
Q3 FY2023Sep 30, 2023-$5.17M–
Q2 FY2023Jun 30, 2023-$4.90M–
Q1 FY2023Mar 31, 2023-$1.61M–
Q4 FY2022Dec 31, 2022-$1.56M–
Q3 FY2022Sep 30, 2022-$7.92M-308.5%
Q2 FY2022Jun 30, 2022-$4.45M–
Q1 FY2022Mar 31, 2022-$9.54M-200.9%
Q4 FY2021Dec 31, 2021-$4.88M–
Q3 FY2021Sep 30, 2021$3.80M–
Q2 FY2021Jun 30, 2021-$6.39M–
Q1 FY2021Mar 31, 2021$9.45M–

More SAB Biotherapeutics figures

See a number that looks wrong?